Explore

Trendline Trendline
EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding

EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding

EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding
Trendline Trendline
EyePoint Reports Q1 2026 Financial Results and Advances in Retinal Disease Therapies

EyePoint Reports Q1 2026 Financial Results and Advances in Retinal Disease Therapies

EyePoint Reports Q1 2026 Financial Results and Advances in Retinal Disease Therapies
Trendline Trendline
Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results
Trendline Trendline
Cryoport Reports Strong Q1 2026 Financial Results with Revenue Growth

Cryoport Reports Strong Q1 2026 Financial Results with Revenue Growth

Cryoport Reports Strong Q1 2026 Financial Results with Revenue Growth
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Epirium Bio Unveils Promising Preclinical Data on 15-PGDH Inhibitors for Inflammatory Bowel Disease

Epirium Bio Unveils Promising Preclinical Data on 15-PGDH Inhibitors for Inflammatory Bowel Disease

Epirium Bio Unveils Promising Preclinical Data on 15-PGDH Inhibitors for Inflammatory Bowel Disease
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Nuvectis Pharma Reports Increased Net Loss in Q1 2026
Trendline Trendline
Atossa Therapeutics' Endoxifen Trial Shows Promise in Reducing Breast Cancer Risk

Atossa Therapeutics' Endoxifen Trial Shows Promise in Reducing Breast Cancer Risk

Atossa Therapeutics' Endoxifen Trial Shows Promise in Reducing Breast Cancer Risk
Trendline Trendline
Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments

Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments

Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments
Trendline Trendline
Compass Pathways to Release Q1 2026 Financial Results and Updates

Compass Pathways to Release Q1 2026 Financial Results and Updates

Compass Pathways to Release Q1 2026 Financial Results and Updates
Trendline Trendline
Cryoport Reports Strong Q1 2026 Financial Results with Increased Clinical Trials

Cryoport Reports Strong Q1 2026 Financial Results with Increased Clinical Trials

Cryoport Reports Strong Q1 2026 Financial Results with Increased Clinical Trials
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates